METROPOLIS.NSE · Metropolis Healthcare Limited

-

Please sign in to comment on METROPOLIS.NSE

1 Comment

Admin

4 years ago

Metropolis Healthcare Limited is currently in a long term uptrend where the price is trading 35.2% above its 200 day moving average.

From a valuation standpoint, the stock is 152.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12.1.

Metropolis Healthcare Limited's total revenue rose by 23.3% to $3B since the same quarter in the previous year.

Its net income has increased by 39.2% to $586M since the same quarter in the previous year.

Finally, its free cash flow fell by 8.8% to $935M since the same quarter in the previous year.

Based on the above factors, Metropolis Healthcare Limited gets an overall score of 3/5.

Sector	Healthcare
Industry	Diagnostics & Research
Exchange	NSE
CurrencyCode	INR
ISIN	INE112L01020

Market Cap	91B
PE Ratio	59.17
Target Price	2061.389
Beta	0.12
Dividend Yield	None

ABOUT

Metropolis Healthcare Limited

Metropolis Healthcare Limited provides diagnostic services in India and internationally. The company offers clinical laboratory testing, and profiles services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates. Its tests and profiles are used for prediction, early detection, diagnostic screening, and confirmation and/or monitoring of the disease. In addition, the company offers corporate wellness, laboratory in, and clinical research services. Metropolis Healthcare Limited was founded in 1981 and is headquartered in Mumbai, India.

METROPOLIS.NSE · Metropolis Healthcare Limited

-

Metropolis Healthcare Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Metropolis Healthcare Limited using a moving average strategy